Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Defactinib and Avutometinib in Metastatic Uveal Melanoma
NCT04720417Phase 2Terminated
- Sponsor
- Thomas Jefferson University
- Start
- Jan 2021
- Primary completion
- Apr 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of avutometinib and defactinib in uveal melanoma (UM), sponsored by Thomas Jefferson University. Started Jan 2021; status: terminated.
02
Drugs
avutometinibdefactinib
03
Conditions
uveal melanoma (UM)
Beyond the preview
Go deeper on NCT04720417.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04720417.